InterCure Ltd. (NASDAQ:INCR) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET

Company Participants

Alexander Rabinovitch - CEO & Director

Amos Cohen - CFO

Conference Call Participants

Vivien Azer - Cowen and Company

Matt Bottomley - Canaccord Genuity

Pablo Zuanic - Zuanic & Associates

Operator

Thank you for standing by, and welcome to InterCure's Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer. [Operator Instructions]

I would now like to hand the call over to [Ori Mendelbaum] (ph), Investor Relations. Please go ahead.

Unidentified Company Representative

Thank you, Latif, and good afternoon, everyone, and welcome to InterCure’s fourth quarter and Full Year 2022 results conference call and webcast. A copy of the company's earnings press release is available on the News & Events section of our website at intercure.co.

With me on today's call are Alex Rabinovitch, InterCure's Chief Executive Officer; and Amos Cohen, the company's Chief Financial Officer. Today, we'll review the highlights and financial results for the fourth quarter and full year ended December, 2022, as well as more recent developments. Following these formal remarks, we will be prepared to answer your questions.

But before we begin, please let me remind you that during this conference call, InterCure's management may make forward-looking statements made within the meaning of applicable security laws. Forward-looking statements may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These forward-looking statements are based on current expectations that are subject to a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied in such statements.

Also, please note that unless otherwise indicated all amounts discuses in this call and expressed today are in Canadian dollars or new Israeli shekels. Additionally, please note that the results mentioned are deemed solely to the company's operation in the cannabis sector unless otherwise specified.

And with that, I will turn over the call to Alex Rabinovitch, InterCure’s CEO, Alex, please go ahead.

Alexander Rabinovitch

Thank you, Ori. Hello everyone, and thank you for joining us for our fourth quarter and full year 2022 earnings call. 2022 was a rather successful year for InterCure as we continue to solidify our position as the largest fastest growing and profitable cannabis company outside North America. In line with our profitable growth strategy, we executed well on all fronts. This resulted in a strong financial and operating results, while further positioning InterCure for continued growth.